- Home
- ACAD vs RDNT Comparison
ACAD vs RDNT Comparison
Compare ACAD & RDNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- RDNT
- Stock Information
- Founded
- ACAD 1993
- RDNT 1985
- Country
- ACAD United States
- RDNT United States
- Employees
- ACAD N/A
- RDNT N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- RDNT Medical Specialities
- Sector
- ACAD Health Care
- RDNT Health Care
- Exchange
- ACAD Nasdaq
- RDNT Nasdaq
- Market Cap
- ACAD 4.3B
- RDNT 5.2B
- IPO Year
- ACAD 2004
- RDNT 1986
- Fundamental
- Price
- ACAD $21.31
- RDNT N/A
- Analyst Decision
- ACAD Buy
- RDNT Strong Buy
- Analyst Count
- ACAD 21
- RDNT 5
- Target Price
- ACAD $29.25
- RDNT $76.80
- AVG Volume (30 Days)
- ACAD 2.3M
- RDNT 673.7K
- Earning Date
- ACAD 11-05-2025
- RDNT 11-10-2025
- Dividend Yield
- ACAD N/A
- RDNT N/A
- EPS Growth
- ACAD 615.00
- RDNT N/A
- EPS
- ACAD 1.33
- RDNT N/A
- Revenue
- ACAD $1,018,885,000.00
- RDNT $1,907,872,000.00
- Revenue This Year
- ACAD $14.01
- RDNT $10.02
- Revenue Next Year
- ACAD $11.81
- RDNT $8.54
- P/E Ratio
- ACAD $16.07
- RDNT N/A
- Revenue Growth
- ACAD 14.41
- RDNT 11.33
- 52 Week Low
- ACAD $13.40
- RDNT $45.00
- 52 Week High
- ACAD $26.65
- RDNT $93.65
- Technical
- Relative Strength Index (RSI)
- ACAD 33.94
- RDNT 61.63
- Support Level
- ACAD $21.32
- RDNT $76.97
- Resistance Level
- ACAD $21.96
- RDNT $79.68
- Average True Range (ATR)
- ACAD 0.60
- RDNT 1.83
- MACD
- ACAD -0.10
- RDNT -0.24
- Stochastic Oscillator
- ACAD 30.11
- RDNT 59.73
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About RDNT RadNet Inc.
RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments: Imaging Center segment and Digital Health segment. The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), and fluoroscopy. The Digital Health segment develops and deploys clinical applications to enhance the interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics.